IMMUNODIAGNOSTIC SYSTEMS HOLDINGS LIMITED

Get an alert when IMMUNODIAGNOSTIC SYSTEMS HOLDINGS LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-29

Confirmation statement due

2026-06-18 (in 1mo)

Last made up 2025-06-04

Watchouts

None on the register

Cash

£4M

+103.1% highest in 3 filed years

Net assets

£51M

-18% lowest in 3 filed years

Employees

0% vs 2023

Profit before tax

£1M

+381.2% highest in 3 filed years

Net assets

3-year trend · vs Health Care median

IMMUNODIAGNOSTIC SYSTEMS HOLDINGS LIMITED·Health Care median · n=826

Accounts

3-year trend · latest reflected 2024-12-29

Metric	2022-12-31	2023-12-31	2024-12-29
Turnover	—	—	—
Operating profit	—	—	—
Profit before tax	£215,401	£210,213	£1,011,641
Net profit	£215,401	£237,376	£988,658
Cash	£1,403,925	£1,728,528	£3,510,420
Total assets less current liabilities	£62,024,963	£62,254,959	£51,046,817
Net assets	£62,017,583	£62,254,959	£51,043,617
Equity	£62,017,583	£62,254,959	£51,043,617
Average employees	16	18	18
Wages	£1,470,553	£1,660,901	£1,307,532

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Audit & accounting basis

Accounting basis: FRS 102
Reporting scope: Standalone (parent only)
Auditor: Azets Audit Services
Audit opinion: Unqualified (clean)
Going concern: Affirmed
“The Directors have, at the time of approving the financial statements, considered the applicability of the going concern basis in the preparation of these financial statements. This included a consideration of the company's cash reserves (intercompany loan) and internal forecasts of the financial results. In addition, the Company has received a letter of support from Revvity Inc, their ultimate parent company to ensure financial support is provided going forward, as such, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the financial statements.”

Group structure

IMMUNODIAGNOSTIC SYSTEMS HOLDINGS LIMITED · parent
1. Immunodiagnostic Systems Limited 100% · UK · Manufacture, development and sale of immunoassays and sale of immunoanalysers
2. Immunodiagnostic Systems SA 100% · Belgium · Manufacture, development and sale of immunoassays
3. Immunodiagnostic Systems France SAS 100% · France · Manufacture, development and sale of immunoassays and manufacture, development and sale of immunoanalysers
4. Immunodiagnostic Systems Deutschland 100% · Germany · Sale of immunoassays and immunoanalysers
5. Suomen Bioanalytikka Oy (SBA Sciences Ltd) 100% · Finland · Dormant
6. IDS Brasil Diagnosticos Ltda 100% · Brazil · Sale of immunoassays and immunoanalysers
7. Dia. Metra S.r.l 100% · Italy · Manufacture, development and sale of immunoassays

Significant events

“The increase in the current period is mainly a result of the exceptional costs within the prior year for the loss of office of two Directors during that period.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

2 active · 31 resigned

Name	Role	Appointed	Born	Nationality
BEECKER, Dirk	Director	2023-01-03	Sep 1965	German
HEALY, John Leo	Director	2025-10-13	Feb 1960	American

Show 31 resigned officers

Name	Role	Appointed	Resigned
DAVISON, Andrew John	Secretary	2012-12-13	2016-03-15
HAILES, Paul	Secretary	2004-06-04	2012-03-31
MARTIN, Paul James	Secretary	2016-03-15	2021-10-15
MURRAY, Gerard Thomas	Secretary	2012-04-01	2012-12-13
BLAIR, Edward Duncan, Dr	Director	2004-12-22	2015-08-04
CAMPE, Till Bengt	Director	2014-11-25	2018-06-30
COOKSON, Christopher Ian	Director	2007-11-01	2012-06-22
DAHLEN, Patrik Olof, Dr	Director	2009-12-11	2015-01-04
DIXON, Gareth Mark	Director	2022-01-18	2024-01-12
DRACUP, William Michael	Director	2004-12-22	2009-09-04
DUGGAN, Roger Thomas Patrick, Dr	Director	2004-06-04	2012-09-14
DUVAL, Regis Jacques	Director	2017-03-31	2017-10-31
EVANS, David Eric	Director	2004-06-04	2011-09-08
GARRITY, Martha Louise	Director	2007-02-01	2013-06-20
HAILES, Paul	Director	2004-06-04	2012-03-31
KASPAR, Klaus Peter	Director	2015-11-01	2021-07-12
LACALLE, Patricio	Director	2015-04-01	2017-03-31
LEE, Phillip Dukeal Kwaiy, Dr	Director	2005-09-26	2006-05-12
MARTIN, Anthony Francis, Dr	Director	2011-09-08	2014-11-25
MARTIN, Paul James	Director	2016-01-04	2021-10-15
MITTON, Nicola	Director	2024-01-01	2025-09-29
MURRAY, Gerard Thomas	Director	2012-04-01	2012-11-30
ROUSSEAU, Alain Michel	Director	2007-08-31	2013-06-20
SACKERS, Roland	Director	2011-06-01	2018-06-30
SCHLUMBERGER, Wolfgang, Dr	Director	2021-07-13	2022-12-31
STUUT, Jaap	Director	2017-11-01	2023-12-31
WILKS, Antony	Director	2007-01-26	2011-09-01
WILLIAMSON, Peter John	Director	2015-06-15	2021-07-12
WITTEK, Burkhard, Dr	Director	2014-11-25	2021-07-12
WITTEK, Burkhard, Dr	Director	2009-10-20	2014-03-06
YATES, Christopher Henry Francis	Director	2013-03-04	2015-06-29

Ownership

Persons with significant control

Name	Kind	Nature of control	Notified	Status
Revvity (Uk) Holdings Limited	Corporate entity	Shares 75–100%	2021-07-12	Active
Dr Burkhard Wittek	Individual	Voting 25–50%	2017-06-26	Ceased 2021-07-12

Filing timeline

Last 20 of 229 total filings

Date	Type	Category	Description
2025-11-24	AA	accounts	Accounts with accounts type full	PDF
2025-10-13	AP01	officers	Appoint person director company with name date	PDF
2025-10-13	TM01	officers	Termination director company with name termination date	PDF
2025-06-10	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2024-09-27	AA	accounts	Accounts with accounts type full	PDF
2024-06-06	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2024-01-14	TM01	officers	Termination director company with name termination date	PDF
2024-01-05	AP01	officers	Appoint person director company with name date	PDF
2024-01-05	TM01	officers	Termination director company with name termination date	PDF
2023-06-22	AA	accounts	Accounts with accounts type full
2023-06-14	CS01	confirmation-statement	Confirmation statement with updates	PDF
2023-06-05	PSC05	persons-with-significant-control	Change to a person with significant control	PDF
2023-01-13	AP01	officers	Appoint person director company with name date	PDF
2023-01-13	TM01	officers	Termination director company with name termination date	PDF
2022-09-21	AA	accounts	Accounts with accounts type full
2022-06-08	CS01	confirmation-statement	Confirmation statement with updates	PDF
2022-01-31	AP01	officers	Appoint person director company with name date	PDF
2021-10-29	AA	accounts	Accounts with accounts type group
2021-10-15	TM01	officers	Termination director company with name termination date	PDF
2021-10-15	TM02	officers	Termination secretary company with name termination date	PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings: 4
Capital events: 0
Officers appointed: 1
Officers resigned: 1

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-29 vs 2023-12-31

Turnover

—

Not reported
Cash

+103.1%

£1,728,528 £3,510,420

highest in 3 filed years
Net assets

-18%

£62,254,959 £51,043,617

lowest in 3 filed years
Employees

0%

18 18
Profit before tax

+381.2%

£210,213 £1,011,641

highest in 3 filed years
Wages

-21.3%

£1,660,901 £1,307,532

lowest in 3 filed years

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers

Official Companies House page